Starpharma Holdings Limited (SPHRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -19.83 Million AUD | 26.3% |
| 2023 | -26.9 Million AUD | 35.52% |
| 2022 | -41.72 Million AUD | 29.67% |
| 2021 | -59.33 Million AUD | -108.33% |
| 2020 | -28.48 Million AUD | 30.92% |
| 2019 | -41.22 Million AUD | 19.59% |
| 2018 | -51.27 Million AUD | 16.11% |
| 2017 | -61.11 Million AUD | -33.0% |
| 2016 | -45.95 Million AUD | -49.2% |
| 2015 | -30.8 Million AUD | -28.59% |
| 2014 | -23.95 Million AUD | 29.01% |
| 2013 | -33.74 Million AUD | 20.93% |
| 2012 | -42.67 Million AUD | -126.35% |
| 2011 | -18.85 Million AUD | 16.92% |
| 2010 | -22.69 Million AUD | -100.77% |
| 2009 | -11.3 Million AUD | -59.97% |
| 2008 | -7.06 Million AUD | 27.5% |
| 2007 | -9.74 Million AUD | 29.52% |
| 2006 | -13.82 Million AUD | -72.26% |
| 2005 | -8.02 Million AUD | 48.06% |
| 2004 | -15.45 Million AUD | -102.61% |
| 2003 | -7.62 Million AUD | 56.25% |
| 2002 | -17.43 Million AUD | 31.39% |
| 2001 | -25.41 Million AUD | 9.5% |
| 2000 | -28.07 Million AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -22.58 Million AUD | 22.13% |
| 2024 Q4 | -19.83 Million AUD | 12.19% |
| 2024 FY | -19.83 Million AUD | 26.3% |
| 2024 Q1 | -29.77 Million AUD | 28.65% |
| 2024 Q2 | -29 Million AUD | 2.59% |
| 2023 Q1 | -36.9 Million AUD | 11.55% |
| 2023 FY | -26.9 Million AUD | 35.52% |
| 2023 Q4 | -41.72 Million AUD | -50.91% |
| 2023 Q3 | -27.65 Million AUD | 23.59% |
| 2023 Q2 | -36.18 Million AUD | 1.95% |
| 2022 FY | -41.72 Million AUD | 29.67% |
| 2022 Q4 | -41.72 Million AUD | 1.64% |
| 2022 Q2 | -47.54 Million AUD | 1.64% |
| 2022 Q3 | -42.42 Million AUD | 10.77% |
| 2022 Q1 | -48.34 Million AUD | 18.53% |
| 2021 Q2 | -68.77 Million AUD | 0.96% |
| 2021 Q1 | -69.44 Million AUD | -143.84% |
| 2021 Q3 | -60.02 Million AUD | 12.73% |
| 2021 Q4 | -59.33 Million AUD | 1.15% |
| 2021 FY | -59.33 Million AUD | -108.33% |
| 2020 Q2 | -34 Million AUD | 1.71% |
| 2020 Q1 | -34.59 Million AUD | 16.08% |
| 2020 FY | -28.48 Million AUD | 30.92% |
| 2020 Q4 | -28.48 Million AUD | 2.08% |
| 2020 Q3 | -29.08 Million AUD | 14.47% |
| 2019 Q1 | -44.39 Million AUD | 13.42% |
| 2019 FY | -41.22 Million AUD | 19.59% |
| 2019 Q2 | -44.39 Million AUD | 0.0% |
| 2019 Q3 | -41.25 Million AUD | 7.07% |
| 2019 Q4 | -41.22 Million AUD | 0.06% |
| 2018 Q2 | -49.86 Million AUD | 0.0% |
| 2018 FY | -51.27 Million AUD | 16.11% |
| 2018 Q4 | -51.27 Million AUD | 0.05% |
| 2018 Q1 | -49.86 Million AUD | 18.41% |
| 2018 Q3 | -51.29 Million AUD | -2.87% |
| 2017 Q3 | -61.14 Million AUD | -68.53% |
| 2017 FY | -61.11 Million AUD | -33.0% |
| 2017 Q1 | -36.28 Million AUD | 21.05% |
| 2017 Q2 | -36.28 Million AUD | 0.0% |
| 2017 Q4 | -61.11 Million AUD | 0.04% |
| 2016 Q1 | -54.68 Million AUD | -77.55% |
| 2016 Q4 | -45.95 Million AUD | 0.04% |
| 2016 Q2 | -54.68 Million AUD | 0.0% |
| 2016 Q3 | -45.97 Million AUD | 15.93% |
| 2016 FY | -45.95 Million AUD | -49.2% |
| 2015 FY | -30.8 Million AUD | -28.59% |
| 2015 Q2 | -39.28 Million AUD | 0.0% |
| 2015 Q4 | -30.8 Million AUD | 0.1% |
| 2015 Q3 | -30.83 Million AUD | 21.52% |
| 2015 Q1 | -39.28 Million AUD | -64.01% |
| 2014 Q3 | -23.98 Million AUD | 13.65% |
| 2014 Q1 | -27.77 Million AUD | 17.69% |
| 2014 FY | -23.95 Million AUD | 29.01% |
| 2014 Q4 | -23.95 Million AUD | 0.11% |
| 2014 Q2 | -27.77 Million AUD | 0.0% |
| 2013 Q3 | -33.76 Million AUD | -1.76% |
| 2013 Q4 | -33.74 Million AUD | 0.07% |
| 2013 FY | -33.74 Million AUD | 20.93% |
| 2013 Q1 | -33.18 Million AUD | 22.24% |
| 2013 Q2 | -33.18 Million AUD | 0.0% |
| 2012 FY | -42.67 Million AUD | -126.35% |
| 2012 Q4 | -42.67 Million AUD | 0.0% |
| 2011 FY | -18.85 Million AUD | 16.92% |
| 2011 Q4 | -18.85 Million AUD | 0.0% |
| 2010 Q4 | -22.69 Million AUD | 0.0% |
| 2010 FY | -22.69 Million AUD | -100.77% |
| 2009 Q4 | -11.3 Million AUD | 0.0% |
| 2009 FY | -11.3 Million AUD | -59.97% |
| 2008 FY | -7.06 Million AUD | 27.5% |
| 2008 Q4 | -7.06 Million AUD | 0.0% |
| 2007 FY | -9.74 Million AUD | 29.52% |
| 2007 Q4 | -9.74 Million AUD | 0.0% |
| 2006 Q4 | -13.82 Million AUD | 0.0% |
| 2006 FY | -13.82 Million AUD | -72.26% |
| 2005 FY | -8.02 Million AUD | 48.06% |
| 2005 Q4 | -8.02 Million AUD | 0.0% |
| 2004 Q4 | -15.45 Million AUD | 0.0% |
| 2004 FY | -15.45 Million AUD | -102.61% |
| 2003 FY | -7.62 Million AUD | 56.25% |
| 2003 Q4 | -7.62 Million AUD | 0.0% |
| 2002 FY | -17.43 Million AUD | 31.39% |
| 2002 Q4 | -17.43 Million AUD | 0.0% |
| 2001 FY | -25.41 Million AUD | 9.5% |
| 2001 Q4 | -25.41 Million AUD | 0.0% |
| 2000 FY | -28.07 Million AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -1513793.13% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -214.568% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 3286.56% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -7844.876% |
| Qrons Inc. | 351.42 Thousand USD | 5743.277% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 3222.328% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 146.344% |
| BioStem Technologies, Inc. | 4.47 Million USD | 543.469% |
| Skye Bioscience, Inc. | -5.72 Million USD | -246.629% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -97077.577% |
| Rebus Holdings, Inc. | 305 Thousand USD | 6602.295% |
| CSL Limited | 10.52 Billion USD | 100.188% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 145.66% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 197.81% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 99923.828% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 451.11% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 225.814% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 581.59% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 5035.187% |
| SQZ Biotechnologies Company | -36.23 Million USD | 45.273% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 984.475% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 2238.945% |
| Mesoblast Limited | 55.85 Million USD | 135.504% |
| Marizyme, Inc. | 18.56 Million USD | 206.801% |
| Genus plc | 190.6 Million USD | 110.405% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 987.008% |
| Pharming Group N.V. | 109.8 Million USD | 118.061% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 2405.4% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1733.759% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 3016.471% |
| ContraFect Corporation | -6.02 Million USD | -229.107% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 14829.759% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1816.419% |
| IMV Inc. | 7.67 Million USD | 358.548% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 460.458% |
| MultiCell Technologies, Inc. | 90.04 USD | 22025866.326% |
| ONE Bio Corp. | 9.04 Million USD | 319.38% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -2601.988% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 253.19% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 1549.738% |
| Q BioMed Inc. | 4.06 Million USD | 588.472% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 164.908% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 2068.015% |
| Biomind Labs Inc. | 711.4 Thousand USD | 2887.735% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 132.755% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 1091.902% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 254.858% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 5613.33% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 14285.574% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 1000.644% |
| GB Sciences, Inc. | 1.74 Million USD | 1234.998% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -10690.694% |
| HST Global, Inc. | 96.79 Thousand USD | 20589.085% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 9717.054% |
| Halberd Corporation | 144.72 Thousand USD | 13803.609% |
| Enzolytics Inc. | 981.65 Thousand USD | 2120.26% |
| Agentix Corp. | 37.63 Thousand USD | 52801.23% |
| Resverlogix Corp. | 6.45 Million USD | 407.425% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -2846.416% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.022% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 57.815% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 380.471% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 832.182% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -124.346% |
| AVAX Technologies, Inc. | -5.9 Million USD | -235.953% |
| Zenith Capital Corp. | 10.06 Thousand USD | 197158.824% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.131% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 9994.628% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 931.17% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 12155.267% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -108165.094% |
| Kadimastem Ltd | -253.1 Thousand USD | -7735.576% |
| Helix BioMedix, Inc. | -2.57 Million USD | -671.664% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 9954.214% |
| LadRx Corporation | -2.03 Million USD | -873.842% |
| Cell Source, Inc. | 9.23 Million USD | 314.819% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 3222.328% |
| NovAccess Global Inc. | 2.17 Million USD | 1010.366% |
| Affymax, Inc. | -5.59 Million USD | -254.333% |
| Itoco Inc. | 228.3 Thousand USD | 8786.625% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 14683.532% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 500.081% |
| Mobile Lads Corp. | 484.23 Thousand USD | 4195.558% |
| CytoDyn Inc. | 20.26 Million USD | 197.878% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -3065124.111% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -213875.75% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 357.358% |
| SYBLEU INC | 473.71 Thousand USD | 4286.492% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 544.961% |
| International Stem Cell Corporation | 2.59 Million USD | 865.714% |
| Bioxytran, Inc. | 1.89 Million USD | 1144.386% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 31875.431% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 1009.349% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 677.519% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 331.872% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 2666.894% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -1486.56% |
| Neutra Corp. | 52.18 Thousand USD | 38101.801% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -696.786% |
| PureTech Health plc | -167.19 Million USD | 88.139% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -7997.735% |
| IXICO plc | -4.44 Million USD | -346.206% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 250.026% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 136.156% |
| CSL Limited | 10.52 Billion USD | 100.188% |
| Cellectis S.A. | -43.81 Million USD | 54.741% |